Peptide Research Spotlights
In-depth, evidence-first breakdowns of the breakthroughs, approvals, and regulatory shifts shaping peptide science in 2026 — updated as the field moves.
Semaglutide vs Tirzepatide
Ozempic, Wegovy, semaglutide and Mounjaro explained — mechanism and efficacy.
Read analysis
Tirzepatide (Mounjaro) in Israel
The GLP-1/GIP dual agonist — SURMOUNT data, Israel status, and safety.
Read analysis
Tesamorelin: The GHRH Analog
What the research really shows on this FDA-approved GHRH peptide.
Read analysis
NAD+ & Longevity
What the research shows on NMN, NR and aging — and where hype skips the data.
Read analysisThe GLP-1 Compounding Crackdown
Why grey-market peptides got riskier as the FDA moves toward a permanent ban.
Read analysisOrforglipron: The First Oral GLP-1 Pill
The first FDA-approved GLP-1 taken as a daily pill — no injection, no cold chain.
Read analysisStay Ahead of Peptide Research
Join 12,000+ researchers, clinicians, and biohackers who receive weekly updates on new studies, regulatory changes, and emerging peptides. No spam. Unsubscribe anytime.
We respect your privacy. No data sold. No spam.